Investigational drug · Phase 2
ABSK061
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "ABSK061"
First trial start
2024
Nov 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABSK061", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-Gastric/Gastroesophageal Junction Cancer
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer
- Solid Tumors
- Achondroplasia
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Achondroplasia · Oncology · Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ABSK061" as an intervention, largest first.
Abbisko Therapeutics Co, LtdIndustry
NCT06632262 · 202 participants (planned) · Start Nov 13, 2024 · Primary completion Nov 30, 2029
Drug: ABSK061 + ABSK043; ABSK061+ABSK043 in combination with CAPOX · For: HER2-Gastric/Gastroesophageal Junction Cancer; Urothelial Carcinoma; Non-Small Cell Lung Cancer and 1 more
Sites: Guiyang, China; Shijiazhuang, China; Harbin, China · 21 sites in all
- A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With AchondroplasiaNot yet recruiting
Abbisko Therapeutics Co, LtdIndustry
NCT07297875 · 110 participants (planned) · Start Dec 10, 2025 · Primary completion Dec 15, 2028
Drug: ABSK061 · For: Achondroplasia
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 7 sites in all
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid TumorsStatus unknown
Abbisko Therapeutics Co, LtdIndustry
NCT05244551 · 85 participants (planned) · Start Jun 30, 2022 · Primary completion Apr 30, 2025
Drug: ABSK061 · For: Solid Tumor
Sites: Dallas, Texas; Shanghai, China; Bengbu, China · 22 sites in all
Abbisko Therapeutics Co, LtdIndustry
NCT07007546 · 42 participants · Start May 17, 2025 · Primary completion Jul 30, 2025
Drug: ABSK061; ABSK061 and 1 more · For: Healthy
Sites: Wuxi, China
Abbisko Therapeutics Co, LtdIndustry
NCT06306872 · 40 participants · Start Feb 23, 2024 · Primary completion Sep 30, 2025
Drug: Sequence A ABSK-011; Sequence B ABSK-011 · For: Healthy Subjects
Sites: Wuxi, China
Newest research
PubMed records naming it or its code names, newest first.
- Next-generation isoform-selective fibroblast growth factor receptor inhibitors.
Chen L · Trends Pharmacol Sci 2025
Also in development for HER2-Gastric/Gastroesophageal Junction Cancer
- ABSK043Phase 24 trials
Abbisko Therapeutics Co, Ltd · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive, HER2-Gastric/Gastroesophageal Junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.